2025-12-29 - Analysis Report
Okay, here's a comprehensive analysis of Natera Inc. (NTRA), based on the data you provided.

**Company Overview:** Natera Inc. is a diagnostics company focused on cell-free DNA testing, primarily for reproductive health and oncology.

**1) Return Rate Comparison & Alpha/Beta Analysis**

**Numbers:**

*   **NTRA Cumulative Return:** 139.49%
*   **VOO (S&P 500) Cumulative Return:** 103.47%
*   **Divergence:** 36.5 (Relative Divergence: 47.5)

**Analysis:**

*   NTRA has significantly outperformed the S&P 500 over the period considered.
*   The divergence of 36.5 indicates that NTRA's performance has varied considerably compared to VOO. A relative divergence of 47.5 means the current difference is near the middle of its historical range.

**Alpha/Beta Analysis Table:**

| Year       | CAGR    | MDD    | Alpha   | Beta   | Cap(B) |
| :---------- | :------ | :----- | :------ | :----- | :------ |
| 2015-2017  | -10.0%  | 70.1%  | -34.0%  | -0.2   | 1.2     |
| 2016-2018  | 22.0%   | 80.0%  | 6.0%    | 0.1    | 1.9     |
| 2017-2019  | 50.0%   | 80.0%  | 28.0%   | 1.0    | 4.7     |
| 2018-2020  | 186.0%  | 80.5%  | 163.0%  | 1.1    | 13.9    |
| 2019-2021  | 96.0%   | 80.5%  | 49.0%   | 1.6    | 13.0    |
| 2020-2022  | -77.0%  | 80.5%  | -76.0%  | 0.1    | 5.6     |
| 2021-2023  | -194.0% | 76.6%  | -195.0% | -1.1   | 8.7     |
| 2022-2024  | 8.0%    | 76.6%  | -13.0%  | -1.2   | 22.1    |
| 2023-2025  | 167.0%  | 76.6%  | 99.0%   | 0.1    | 32.6    |

**Analysis:**

*   **CAGR:**  Highly volatile, ranging from negative double digits to positive triple digits, indicating a high-risk, high-reward profile.
*   **MDD:** Consistently high Maximum Drawdown (MDD) figures, all above 70%, confirming significant volatility.
*   **Alpha:** The alpha fluctuates considerably.  Positive alpha (e.g., 2018-2020, 2023-2025) indicates periods of outperformance relative to its risk (beta). Negative alpha indicates underperformance.
*   **Beta:** Beta fluctuates around 1, indicating the stock's volatility is generally in line with the market, but with periods of lower/higher sensitivity.
*   **Cap(B):**  Shows significant growth in market capitalization over the years.

**2) Recent Stock Price Fluctuations**

**Numbers:**

*   **Current Close:** 233.74
*   **Previous Close:** 235.54
*   **Change:** -0.76
*   **5-day SMA:** 234.44
*   **20-day SMA:** 234.37
*   **60-day SMA:** 208.40

**Analysis:**

*   The recent close is slightly down from the previous close.
*   The 5-day and 20-day SMAs are very close, suggesting a period of consolidation in the short-term.
*   The 60-day SMA is significantly lower than the 5-day and 20-day SMAs, indicating an upward trend over the past couple of months.

**3) RSI, PPO Index Indicators, and Expected Return**

**Numbers:**

*   **MRI:** 1.0 (High Investment Recommended)
*   **RSI:** 34.36
*   **PPO:** -0.61
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (4 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00)
*   **Recent Relative Divergence Change:** -0.1 (short-term decline)
*   **Expected Return:** -49.9%

**Analysis:**

*   **MRI:** Suggests high investment recommendation, though this should be viewed with caution alongside other factors.
*   **RSI:** The RSI of 34.36 indicates that the stock might be approaching oversold conditions.
*   **PPO:** The negative PPO (-0.61) suggests that the short-term moving average is below the long-term moving average, indicating a possible downtrend.
*   **Hybrid Signal:**  Recommends buying, considering it "Very Safe".
*   **Recent Relative Divergence Change:**  Confirms a recent short-term decline.
*   **Expected Return:** A concerning negative expected return (-49.9%) suggests potential headwinds and caution is warranted.

**4) Recent News & Significant Events**

*   **Vontobel Holding Ltd. Increases Stock Position:**  A positive signal, indicating institutional confidence.
*   **Investor Beat the Market for 3 Decades: 3 Stocks He’s Buying Now:**  Potentially positive if NTRA is one of those stocks, indicating confidence from a successful investor.
*   **Cell-free DNA company is taking the stage at a big health conference:** Good for visibility and potential partnerships/interest.
*   **3 Reasons We’re Fans of Natera (NTRA):**  Positive sentiment.
*   **Natera Stock Analysis: Why This Cancer Testing Stock Could Triple:**  Very bullish outlook.
*   **Why Natera Remains A 'Hold' For Me Despite Surging MRD Growth And Fatter Margins:**  More cautious, but acknowledges positive developments.

**Analysis:**

*   Recent news presents a mixed picture. Institutional buying and positive articles provide tailwinds, while hold recommendations offer some caution. The articles highlight growth in cancer testing as a driver.

**4-2) Analyst Opinions**

**Numbers:**

*   **Consensus:** Strong Buy (1.47)
*   **Opinions:** 19
*   **Target Price:** Avg: 246.26 / High: 285.00 / Low: 186.00

**Analysis:**

*   Strong analyst consensus with a "Strong Buy" rating.
*   The average target price is slightly above the current price, suggesting potential upside.
*   No recent rating changes are listed.

**5) Recent Earnings Analysis**

| 날짜       | EPS   | 매출      |
| :---------- | :------ | :---------- |
| 2025-11-07  | -0.64 | 0.59 B$  |
| 2025-08-08  | -0.74 | 0.55 B$  |
| 2025-05-09  | -0.5  | 0.50 B$  |
| 2024-11-12  | -0.26 | 0.44 B$  |
| 2025-11-07  | -0.26 | 0.44 B$  |

**Analysis:**

*   The company is consistently reporting losses per share (negative EPS).
*   Revenue is growing steadily quarter-over-quarter.
* The table is inconsistent and has duplicates.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
| :------------- | :-------- | :-------------- |
| 2025-09-30 | $0.59B    | 64.91%          |
| 2025-06-30 | $0.55B    | 63.41%          |
| 2025-03-31 | $0.50B    | 63.12%          |
| 2024-12-31 | $0.48B    | 62.94%          |
| 2024-09-30 | $0.44B    | 61.79%          |

**Analysis:**

*   Consistent revenue growth over the past five quarters.
*   High and increasing profit margins.

**Capital and Profitability:**

| Quarter      | Equity    | ROE       |
| :------------- | :-------- | :---------- |
| 2025-09-30 | $1.25B    | -6.99%      |
| 2025-06-30 | $1.25B    | -8.10%      |
| 2025-03-31 | $1.24B    | -5.40%      |
| 2024-12-31 | $1.20B    | -4.50%      |
| 2024-09-30 | $0.88B    | -3.60%      |

**Analysis:**

*   Equity is increasing, showing a stronger capital base.
*   Negative Return on Equity (ROE) indicates that the company is not generating profits from shareholder equity.  The ROE has become *more* negative recently, despite the revenue growth.

**7) Comprehensive Analysis**

Natera (NTRA) presents a mixed investment picture:

*   **Positives:**
    *   Significant historical outperformance compared to the S&P 500, though with high volatility.
    *   Strong analyst consensus ("Strong Buy").
    *   Growing revenue and high profit margins.
    *   Increasing equity.
    *   Positive news flow related to institutional investment and potential growth in the cancer testing market.
*   **Negatives:**
    *   Extremely high volatility, as evidenced by the MDD figures.
    *   Consistently negative EPS and negative (and declining) ROE.
    *   A concerning negative expected return, suggesting potential future challenges.
    *   Recent short-term decline.
    *   The alpha/beta analysis reveals inconsistent performance, with periods of significant underperformance relative to risk.

**Conclusion:**

NTRA is a high-risk, high-reward stock. While it has shown significant growth potential and is favored by analysts, its lack of profitability, extreme volatility, and negative expected return necessitate caution. Investors should carefully consider their risk tolerance and conduct further due diligence before investing. While the MRI suggests "High Investment Recommended," the negative expected return and other factors point to the opposite. The strong revenue growth and high profit margins are promising, but the company needs to translate that into profitability to justify its current valuation.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.